Zonisamide (All indications) updated on 04-22-2025

Preterm (< 37 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S16191
R79485		 The NAAED (Zonisamide) (Controls exposed to LTG) (Indications NOS), 2025 Preterm (<37 wk) at least 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 1.19 [0.77;1.82] C
excluded (control group) 		26/228   241/2,461 267 228
ref
S16181
R79483		 The NAAED (Zonisamide) (Controls unexposed, disease free) (Indications NOS), 2025 Preterm (<37 wk) at least 1st trimester prospective cohort unexposed, disease free Adjustment: No 0.76 [0.49;1.18] C 26/228   189/1,311 215 228
ref
Total 1 studies 0.76 [0.49;1.18] 215 228
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF The NAAED (Zonisamide) (Controls unexposed, disease free) (Indications NOS), 2025The NAAED, 2025 1 0.76[0.49; 1.18]2152280%ROB confusion: criticalROB selection: unclearROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: low0.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Zonisamide) (Controls unexposed, disease free) (Indications NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.76[0.49; 1.18]215228 -NAThe NAAED (Zonisamide) (Controls unexposed, disease free) (Indications NOS), 2025 1 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.76[0.49; 1.18]215228 -NAThe NAAED (Zonisamide) (Controls unexposed, disease free) (Indications NOS), 2025 1 Tags Adjustment   - No  - No 0.76[0.49; 1.18]215228 -NAThe NAAED (Zonisamide) (Controls unexposed, disease free) (Indications NOS), 2025 1 All studiesAll studies 0.76[0.49; 1.18]215228 -NAThe NAAED (Zonisamide) (Controls unexposed, disease free) (Indications NOS), 2025 10.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 16191

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.76[0.49; 1.18]215228 -NAThe NAAED (Zonisamide) (Controls unexposed, disease free) (Indications NOS), 2025 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.19[0.77; 1.82]267228 -NAThe NAAED (Zonisamide) (Controls exposed to LTG) (Indications NOS), 2025 10.510.01.0